The ModiFY study
Research type
Research Study
Full title
A Phase 1/2, Multicentre, Open-Label Study of Modi-1 in Patients with Breast, Head and Neck, Ovarian, or Renal Cancer
IRAS ID
298608
Contact name
Robert Miller
Contact email
Sponsor organisation
Scancell Ltd
Eudract number
2021-002061-18
Clinicaltrials.gov Identifier
Duration of Study in the UK
3 years, 11 months, 31 days
Research summary
The purpose of this study is to find out if a new treatment called Modi-1v or Modi-1 can be used safely either on its own or in addition to another treatment called a checkpoint inhibitor to treat Triple Negative Breast Cancer, Head and Neck Cancer, Ovarian Cancer or Kidney Cancer.
The study is expected to enrol up to 144 patients in approximately 20 UK sites.
REC name
East of England - Cambridgeshire and Hertfordshire Research Ethics Committee
REC reference
21/EE/0191
Date of REC Opinion
24 Sep 2021
REC opinion
Further Information Favourable Opinion